GlassScriptPhysician profile
Shawn Ellis
NPI 1851551790
$5,710.18
in general payments reported to CMS, 2019-2025
31 companies · $662 in 2025
The $662 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $508 · 2021: $722 · 2022: $610 · 2023: $1,170 · 2024: $967 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,798.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,610.77 | 2019-2025 | Proclaim, Eterna |
| Medtronic, INC. | $905.09 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Saluda Medical Americas, INC. | $562.74 | 2023-2025 | Evoke, Evoke Scs |
| Si-Bone, INC. | $351.10 | 2021-2023 | |
| Nevro Corp. | $262.89 | 2019-2024 | Senza |
| Boston Scientific Corporation | $255.97 | 2021-2024 | Intracept |
| Pfizer INC. | $247.33 | 2019 | |
| Collegium Pharmaceutical, INC. | $182.37 | 2020-2024 | Belbuca |
| Relievant Medsystems, INC. | $177.85 | 2023 | Intracept |
| Arbor Pharmaceuticals, INC. | $153.38 | 2019-2021 | |
| Genentech USA, INC. | $141.79 | 2020 | |
| Grt US Holding, INC. | $129.83 | 2021-2022 | |
| Spr Therapeutics, INC | $91.93 | 2022-2025 | Sprint Pns System |
| Pacira Therapeutics, INC. | $88.73 | 2020-2021 | |
| Abbvie INC. | $86.33 | 2023-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $59.17 | 2019 | |
| Radius Health, INC. | $55.13 | 2021-2022 | |
| Almatica Pharma LLC | $46.50 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $35.54 | 2024 | Horizant, Edarbi |
| Shionogi INC | $34.67 | 2019 | |
| Curonix LLC | $33.36 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.31 | 2024 | Relistor |
| Averitas Pharma INC. | $26.52 | 2025 | Qutenza |
| Amgen INC. | $26.37 | 2022-2025 | Prolia, Evenity |
| Assertio Therapeutics, INC. | $24.97 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.69 | 2023 | Seglentis |
| Astrazeneca Pharmaceuticals LP | $17.34 | 2019 | |
| Bioventus LLC | $17.26 | 2024 | Durolane |
| Vertiflex, INC. | $13.98 | 2019 | |
| Ucb, INC. | $13.95 | 2022 | |
| Biodelivery Sciences International, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.